VNDA
Closed
Vanda Pharmaceuticals Inc
4.68
-0.04 (-0.85%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 4.72
Day's Range: 4.66 - 4.755
Send
sign up or login to leave a comment!
When Written:
6.8
Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies to address high unmet medical needs. The company was founded in 2002 and is headquartered in Washington, D.C.
Vanda's lead product, Fanapt (iloperidone), is an atypical antipsychotic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. The company also has a pipeline of other product candidates in various stages of development, including Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder, and tradipitant, a treatment for various gastrointestinal disorders.
Vanda is committed to scientific innovation and has a team of experienced researchers and scientists who work to develop new treatments for patients with unmet medical needs. The company also collaborates with academic institutions and other pharmaceutical companies to advance its research and development efforts.
As of 2021, Vanda Pharmaceuticals has a market capitalization of approximately $1.3 billion and employs over 300 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Vanda's lead product, Fanapt (iloperidone), is an atypical antipsychotic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. The company also has a pipeline of other product candidates in various stages of development, including Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder, and tradipitant, a treatment for various gastrointestinal disorders.
Vanda is committed to scientific innovation and has a team of experienced researchers and scientists who work to develop new treatments for patients with unmet medical needs. The company also collaborates with academic institutions and other pharmaceutical companies to advance its research and development efforts.
As of 2021, Vanda Pharmaceuticals has a market capitalization of approximately $1.3 billion and employs over 300 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!